S&P 500   4,205.52
DOW   33,042.78
QQQ   349.98
The "How" and "Why" of Investing in 5G Stocks
146 Pounds of Graphite Needed for Each EV (Ad)
Palantir: The "Sleeper" Play on the AI Revolution
Keep An Eye On These 5 Small-Cap AI Companies
146 Pounds of Graphite Needed for Each EV (Ad)
AI Chip Stock Showdown: The Biggest Winners and Losers
Can Tesla's Supercharger Become the Industry Norm? Ford Says Yes
146 Pounds of Graphite Needed for Each EV (Ad)
Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs
Elizabeth Holmes Is Jailhouse Bound. Disgraced Theranos Founder Begins Prison Sentence
S&P 500   4,205.52
DOW   33,042.78
QQQ   349.98
The "How" and "Why" of Investing in 5G Stocks
146 Pounds of Graphite Needed for Each EV (Ad)
Palantir: The "Sleeper" Play on the AI Revolution
Keep An Eye On These 5 Small-Cap AI Companies
146 Pounds of Graphite Needed for Each EV (Ad)
AI Chip Stock Showdown: The Biggest Winners and Losers
Can Tesla's Supercharger Become the Industry Norm? Ford Says Yes
146 Pounds of Graphite Needed for Each EV (Ad)
Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs
Elizabeth Holmes Is Jailhouse Bound. Disgraced Theranos Founder Begins Prison Sentence
S&P 500   4,205.52
DOW   33,042.78
QQQ   349.98
The "How" and "Why" of Investing in 5G Stocks
146 Pounds of Graphite Needed for Each EV (Ad)
Palantir: The "Sleeper" Play on the AI Revolution
Keep An Eye On These 5 Small-Cap AI Companies
146 Pounds of Graphite Needed for Each EV (Ad)
AI Chip Stock Showdown: The Biggest Winners and Losers
Can Tesla's Supercharger Become the Industry Norm? Ford Says Yes
146 Pounds of Graphite Needed for Each EV (Ad)
Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs
Elizabeth Holmes Is Jailhouse Bound. Disgraced Theranos Founder Begins Prison Sentence
S&P 500   4,205.52
DOW   33,042.78
QQQ   349.98
The "How" and "Why" of Investing in 5G Stocks
146 Pounds of Graphite Needed for Each EV (Ad)
Palantir: The "Sleeper" Play on the AI Revolution
Keep An Eye On These 5 Small-Cap AI Companies
146 Pounds of Graphite Needed for Each EV (Ad)
AI Chip Stock Showdown: The Biggest Winners and Losers
Can Tesla's Supercharger Become the Industry Norm? Ford Says Yes
146 Pounds of Graphite Needed for Each EV (Ad)
Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs
Elizabeth Holmes Is Jailhouse Bound. Disgraced Theranos Founder Begins Prison Sentence
OTCMKTS:ARTH

Arch Therapeutics (ARTH) Stock Forecast, Price & News

$3.10
0.00 (0.00%)
(As of 05/30/2023 ET)
Compare
Today's Range
$3.10
▼
$3.10
50-Day Range
$2.35
▼
$4.90
52-Week Range
$2.02
▼
$12.00
Volume
41 shs
Average Volume
415 shs
Market Capitalization
$4.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort Interest

Arch Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.02% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of Arch Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.03) to $14.47 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.10 out of 5 stars

See Top Rated MarketRank™ Stocks Here

ARTH stock logo

About Arch Therapeutics (OTCMKTS:ARTH) Stock

Arch Therapeutics, Inc. is a development stage biotechnology company, which engages in the development and provision of hemostasis and sealant technology platform. Its product candidates include AC5 Devices, which designed to achieve hemostasis during surgical, wound, and interventional care. The company was founded by Rutledge Ellis-Behnke and Terrence W. Norchi on September 16, 2009 and is headquartered in Framingham, MA.

Receive ARTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARTH Stock News Headlines

May 27, 2023 | americanbankingnews.com
Short Interest in Arch Therapeutics, Inc. (OTCMKTS:ARTH) Rises By 100.0%
May 18, 2023 | americanbankingnews.com
Arch Therapeutics (OTCMKTS:ARTH) Stock Price Passes Below Fifty Day Moving Average of $3.30
May 31, 2023 | Edge On The Street (Ad)
AI Getting Close to Thinking Like Humans
Technology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.
April 25, 2023 | finance.yahoo.com
Arch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)
April 16, 2023 | americanbankingnews.com
Arch Therapeutics, Inc. (OTCMKTS:ARTH) Short Interest Update
April 5, 2023 | finance.yahoo.com
Dedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In Effect
March 20, 2023 | investing.com
Arch Therapeutics Inc (ARTHD)
March 9, 2023 | finance.yahoo.com
Arch Therapeutics’ AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid Services
May 31, 2023 | Edge On The Street (Ad)
The Ignored EV Story Few Investors Know About
Lithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.
March 7, 2023 | finance.yahoo.com
Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government Facilities
February 23, 2023 | benzinga.com
Arch Therapeutics Inc Stock (OTC:ARTHD), Earnings Estimates, EPS, and Revenue
January 24, 2023 | msn.com
Wound products developer Arch Therapeutics files for uplisting, $35M offering (update)
January 18, 2023 | finanznachrichten.de
Arch Therapeutics, Inc.: Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National Exchange
January 18, 2023 | finance.yahoo.com
Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System
January 17, 2023 | finance.yahoo.com
Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National Exchange
December 5, 2022 | finance.yahoo.com
The Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics’ AC5® Advanced Wound System
October 20, 2022 | seekingalpha.com
ARTH Arch Therapeutics, Inc.
October 18, 2022 | yahoo.com
Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Fall
October 11, 2022 | finance.yahoo.com
Arch Therapeutics’ AC5® Advanced Wound System to be Presented with Honors at 2022 Symposium on Advanced Wound Care (SAWC) Fall
September 23, 2022 | finance.yahoo.com
Arch Therapeutics Announces First Shipments of AC5® Advanced Wound System Under New Reimbursement Support Program
September 16, 2022 | finance.yahoo.com
Arch Therapeutics Announces Intent to Uplist from OTC to a National Exchange
September 7, 2022 | finance.yahoo.com
Arch Therapeutics Launches Multi-Site Clinical Study for AC5® Advanced Wound System
July 14, 2022 | benzinga.com
Arch Therapeutics (OTC:ARTH), Short Interest Report
July 7, 2022 | finance.yahoo.com
Arch Therapeutics Raises Approximately $3.5 Million in Convertible Note Financing
June 22, 2022 | finance.yahoo.com
Arch Therapeutics Provides Update on Reimbursement Strategy in Additional Selling Channel
May 9, 2022 | finance.yahoo.com
Arch Therapeutics’ Experts in Wound Care Interview Showcases AC5 Self-Assembling Peptide Technology During Live Session at SAWC Spring
May 9, 2022 | benzinga.com
Arch Therapeutics' Experts in Wound Care Interview Showcases AC5 Self-Assembling Peptide Technology During Live Session at SAWC Spring
See More Headlines
Receive ARTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARTH Company Calendar

Last Earnings
7/23/2020
Today
5/31/2023
Fiscal Year End
9/30/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ARTH
Previous Symbol
NASDAQ:ARTH
CUSIP
N/A
CIK
1537561
Web
www.archtherapeutics.com
Phone
(617) 431-2313
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,280,000.00
Net Margins
-18,293.00%
Pretax Margin
-18,289.75%
Return on Equity
N/A
Return on Assets
-239.38%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.20
Quick Ratio
0.02

Sales & Book Value

Annual Sales
$20,000.00
Price / Sales
199.95
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($3.36) per share
Price / Book
-0.92

Miscellaneous

Outstanding Shares
1,290,000
Free Float
1,161,000
Market Cap
$4.00 million
Optionable
Not Optionable
Beta
0.71

Key Executives

  • Terrence W. Norchi
    Chairman, President & Chief Executive Officer
  • Michael S. Abrams
    Chief Financial Officer & Treasurer
  • Daniel M. Yrigoyen
    Vice President-Sales

Key Competitors

View All Competitors













ARTH Stock - Frequently Asked Questions

How have ARTH shares performed in 2023?

Arch Therapeutics' stock was trading at $0.0260 at the beginning of the year. Since then, ARTH shares have increased by 11,823.1% and is now trading at $3.10.
View the best growth stocks for 2023 here.

Are investors shorting Arch Therapeutics?

Arch Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 200 shares, an increase of 100.0% from the April 30th total of 100 shares. Based on an average trading volume of 1,200 shares, the short-interest ratio is currently 0.2 days.
View Arch Therapeutics' Short Interest.

How were Arch Therapeutics' earnings last quarter?

Arch Therapeutics, Inc. (OTCMKTS:ARTH) issued its quarterly earnings data on Thursday, July, 23rd. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01.

What other stocks do shareholders of Arch Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arch Therapeutics investors own include Anavex Life Sciences (AVXL), POET Technologies (POETF), Aptose Biosciences (APTO), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), SCYNEXIS (SCYX), Bellerophon Therapeutics (BLPH), Sorrento Therapeutics (SRNE), Biocept (BIOC) and Aurinia Pharmaceuticals (AUPH).

What is Arch Therapeutics' stock symbol?

Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."

How do I buy shares of Arch Therapeutics?

Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arch Therapeutics' stock price today?

One share of ARTH stock can currently be purchased for approximately $3.10.

How much money does Arch Therapeutics make?

Arch Therapeutics (OTCMKTS:ARTH) has a market capitalization of $4.00 million and generates $20,000.00 in revenue each year.

How can I contact Arch Therapeutics?

Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The official website for the company is www.archtherapeutics.com. The biotechnology company can be reached via phone at (617) 431-2313 or via email at investors@archtherapeutics.com.

This page (OTCMKTS:ARTH) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -